aspirin plus P2Y12 antagonist
PreclinicalSmall molecule
aspirin plus P2Y12 antagonist is one of 7 small molecule programs targeting Dual Antiplatelet Therapy. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Dual Antiplatelet Therapy
#DrugCompanyPhaseTrials
1Plavix
SanofiApproved
Effient
CCosette Pharmaceuticals, Inc.
Approved
Pradaxa
Boehringer IngelheimPreclinical
Single Antiplatelet Therapy
CChina National Center for Cardiovascular Diseases
Preclinical
aspirin plus P2Y12 antagonist
SSamsung Medical Center
Preclinical
DAPT De-Escalation
SShenyang Northern Hospital
Preclinical
Short DAPT
KKorea University Guro Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SSamsung Medical Center